Treatment of diabetes
First Claim
Patent Images
1. A method for treating diabetes, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a gastrin/CCK receptor ligand and a factor for complementing gastrin for islet neogenesis therapy (a FACGINT), provided that the FACGINT is not an EGF receptor ligand.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions and methods are provided for islet neogenesis therapy comprising a member of a group of factors that complement a gastrin/CCK receptor ligand, with formulations, devices and methods for sustained release delivery and for local delivery to target organs.
-
Citations
110 Claims
- 1. A method for treating diabetes, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a gastrin/CCK receptor ligand and a factor for complementing gastrin for islet neogenesis therapy (a FACGINT), provided that the FACGINT is not an EGF receptor ligand.
-
5. A method for treating diabetes, the method comprising:
-
contacting ex vivo a plurality of cells with a composition comprising at least one FACGINT and a gastrin/CCK receptor ligand, provided that the FACGINT is not an EGF receptor ligand; and
administering the cells to a mammal in need thereof, thereby treating the diabetes. - View Dependent Claims (6, 11, 15)
-
-
13. A method for inducing pancreatic islet neogenesis in a mammal, the method comprising administering to the mammal a composition comprising a combination of a FACGINT and a gastrin/CCK receptor ligand provided that the FACGINT is not an EGF receptor ligand, in an amount sufficient to increase proliferation of islet precursor cells in pancreatic tissue, thereby inducing pancreatic islet neogenesis.
-
14. A method for inducing pancreatic islet neogenesis in a mammal, the method comprising administering a composition comprising a combination of a FACGINT and a gastrin/CCK receptor ligand wherein the FACGINT is not an EGF receptor ligand, in an amount sufficient to increase the number of pancreatic insulin secreting β
- cells in the mammal.
- 16. A composition comprising a gastrin/CCK receptor ligand and a FACGINT, provided that the FACGINT is not an EGF receptor ligand.
- 19. A kit for treating or preventing diabetes, containing a composition comprising a gastrin/CCK receptor ligand and a FACGINT, a container, and instructions for use, provided that the FACGINT is not an EGF receptor ligand.
- 21. A method for expanding and differentiating stem cells into insulin secreting cells in a diabetic recipient of implanted cells, comprising implanting the stem cells in the recipient, and administering to the recipient a composition containing an effective dose of each of a gastrin/CCK receptor ligand and at least one FACGINT provided that the FACGINT is not an EGF receptor ligand.
- 32. A method for reducing an amount of stem cells needed for transplantation to treat human diabetes, the method comprising administering to the recipient an effective dose of each of a gastrin/CCK receptor ligand and a FACGINT provided that the FACGINT is not an EGF receptor ligand, wherein the amount of cells needed is reduced in comparison to an amount of cells needed in the absence of administering the effective dose to an otherwise identical recipient.
-
46. A kit for treatment of a diabetic subject, comprising an immunosuppressive agent, an INT composition comprising a FACGINT provided that the FACGINT is not an EGF receptor ligand, and a container.
-
47. A pharmaceutical composition comprising a FACGINT provided that the FACGINT is not an EGF receptor ligand and an agent for immune suppression.
-
48. A pharmaceutical composition for sustained release of an I.N.T.™
- therapeutic composition, the composition comprising;
a gastrin receptor ligand; and
an EGF receptor ligand or a FACGINT;
wherein at least one of the gastrin receptor ligand, or the EGF receptor ligand or FACGINT, is a sustained release formulation. - View Dependent Claims (50, 51, 52, 53, 54, 55, 56, 57, 62, 64, 65, 66, 67, 68, 69, 70, 71)
- therapeutic composition, the composition comprising;
-
72. A method of reducing frequency of treating a diabetic subject with an I.N.T.™
- composition, the method comprising;
preparing at least one component of the composition as a sustained release formulation; and
administering the composition to the subject according to a protocol having greater intervals between treatments than for the composition not so formulated and otherwise identical. - View Dependent Claims (73, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86)
- composition, the method comprising;
-
74. A method of enhancing efficacy of an I.N.T.™
- composition in a diabetic subject, the method comprising;
administering to the subject an I.N.T.™
composition having at least one component of the composition formulated to produce a sustained release; and
comparing efficacy in treating the subject of an amount of the composition administered to efficacy of a composition not having a component so formulated and otherwise identical, such that the efficacy of the I.N.T.™
composition having a sustained release formulated composition, as measured by a decrease in an amount of the sustained release formulated agent required to reduce or eliminate symptoms of diabetes in the subject, is enhanced. - View Dependent Claims (75)
- composition in a diabetic subject, the method comprising;
-
82. The method according to claim 82, further comprising administering the composition in an effective dose.
-
87. A method of reducing frequency of treating a diabetic subject, the method comprising preparing a device for administering an I.N.T.™
- composition to the subject by continuous release for a prolonged period;
providing the device to the subject; and
re-iterating treating the subject by replacing or refilling the device. - View Dependent Claims (88, 89)
- composition to the subject by continuous release for a prolonged period;
-
90. A method according to claim 87, wherein the device is selected from the group consisting of:
- a degradable implant;
a non-degradable implant;
a mucoadhesive implant;
a transcutaneous patch;
a catheter; and
an iontophoresis device.
- a degradable implant;
-
90-1. A method for expanding and differentiating stem cells into insulin secreting cells in a diabetic recipient of the cells, comprising:
-
implanting the cells in the recipient; and
administering a sustained release composition comprising an effective dose of each of;
a gastrin/CCK receptor ligand; and
a FACGINT or an EGF receptor ligand, wherein the stem cells are expanded and differentiated into insulin secreting cells in the recipient.
-
- 91. A composition for treating diabetes comprising a Glucagon-like peptide-1 (GLP-1) receptor ligand and a gastrin/CCK receptor ligand.
- 93. A composition for treating diabetes comprising a Growth Hormone (GH) receptor ligand and a gastrin/CCK receptor ligand.
- 96. A composition for treating diabetes comprising a prolactin (PL) receptor ligand and a gastrin/CCK receptor ligand.
- 101. A method of treating a diabetic subject comprising administering to the subject a composition comprising a gastrin/CCK receptor ligand and a Glucagon-like peptide-1 (GLP-1) receptor ligand.
-
102. A method of treating a diabetic subject comprising administering to the subject a composition comprising a gastrin/CCK receptor ligand and a Growth Hormone (GH) receptor ligand.
-
103. A method of treating a diabetic subject comprising administering to the subject a composition comprising a gastrin/CCK receptor ligand and a prolactin (PL) receptor ligand.
-
108. A method for expanding a functional β
- cell mass of pancreatic islet transplants in a diabetic patient recipient of a transplant of purified islets, the method comprising administering to the mammal an effective dose of a gastrinCCK receptor ligand and a FACGINT.
-
109. A method of treating human diabetes comprising transplanting a pancreatic islet preparation into a diabetic patient;
- and administering to the patient an effective dose of a gastrin/CCK receptor ligand and a FACGINT.
Specification